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dures. Results: Compared to Non-TRA, TRA was used more commonly in males (70.5%
vs. 65.7%; p<0.0001), but less often in hypertensives (65.7% vs. 69.2%; p<0.0001),
patients with a history of renal failure (3.0% vs. 4.3%; p<0.0001), patients with prior MI
(25.8% vs. 28.6%; p<0.0001) or prior coronary artery bypass graft surgery (11.6% vs.
19.1%). TRA patients were significantly younger (61±12 vs. 63±12 years; p<0.0001) and
more likely to have BMI > 35 (20.1% vs. 16.1%; p<0.0001). Mortality risk was signficantly
lower in TRA patients (0.6% vs. 1.2%; p<0.00001) compared to Non-TRA patients.
Adjusted mortality (observed/expected X observed) was similar between the groups, as
was PCI success. Patients with TRA had a length of hosptial stay 0.5 days shorter than
Non-TRA patients (p<0.0001). Bleeding was less common with TRA (0.7% vs. 1.7%;
p<0.0001) and both males and females had singifncantly less bleeding (0.4% vs. 1.1%
for males, and 1.4% vs. 2.8% for females; both p<0.0001). Multivariate analysis demon-
strated that TRA was idependently associated with less bleeding complications. Conclu-
sions The transradial access is more likely to be used in less severely ill patients, but
outcomes are comparable and there does appear to be less bleeding, both for males and
females.
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Background. Distal embolization during primary angioplasty (PA) may affect myocardial
reperfusion. We evaluated the impact of Abciximab pre-treatment on the entity and quali-
tative composition of PA-induced distal embolization. Methods. Fourty-two consecutive
patients with acute myocardial infarction underwent PA using the non-occlusive distal
protection device FilterWire Ex (Boston Scientific Corp., USA). Abciximab pre-treatment
was performed in 22 patients (52%). The embolic fragments retrieved from the filters
underwent morphometric and histopathological analysis. Serial histological sections (5
micron intervals) were stained with hematoxylin-eosin. Additional histochemical stains
were: Weigert for fibrin, Oil Red-O for lipid droplets, Alcian blue for mucopolisaccharides,
anti M-CSF monoclonal antibodies for macrophages, and anti collagen monoclonal anti-
bodies for collagen fibers. The total debris area was calculated for each patient. Results.
Particles were recovered in 37 out of 42 devices (88%). Abciximab administration did not
significantly reduce number and size of the particles with respect to the control group
(mean number: 21±17 vs 22±27, P=NS; total debris area: 3.7±4.8 vs 3.6±6.0 mm*mm,
P=NS). Particles of fresh thrombus containing fibrin, platelets, and red cells were
observed in 4 abciximab patients and in 5 control patients (20% vs 29%, P=NS); plaque
fragments in 5 and 4 patients (25% vs 24%, P=NS)and partially organized thrombus par-
ticles 11 and 8 patients (55% vs 47%, P=NS). Among clinical and angiographic variables,
only the angiographic signs of high thrombus burden (a cut-off pattern or a minus image
greater than 3 times the reference lumen diameter)were significantly related to the total
debris area at multivariate analysis. Conclusion. Distal embolization occurs in the vast
majority of patients undergoing PA and often incorporates plaque-containing debris and
partially organized clots, which are probably unresponsive to anti-platelet drugs. Accord-
ingly, abciximab pre-treatment does not appear to reduce the embolic burden.
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Background. Adjunctive pharmacotherapy during higher risk percutaneous coronary
intervention (PCI) has historically consisted of a combination of anti-platelet and anti-
thrombin drugs. However, anti-platelet drugs such as eptifibatide that block the glycopro-
tein IIb/IIIa receptor have been shown in-vitro to prevent both platelet aggregation and
thrombin generation. We therefore hypothesized that, for higher risk PCI, eptifibatide-
based anti-platelet therapy accompanied by only limited, specific anti-thrombin therapy
would be efficacious and safe. Methods. In this observational study, we retrospectively
assessed the outcomes of 786 consecutive inpatients (pts) undergoing urgent, higher
risk PCI for treatment of either unstable angina (535 pts), acute pulmonary edema (67
pts), or acute, non-ST segment elevation myocardial infarction (184 pts). PCI techniques
included stent deployment, cutting balloon atherotomy, high speed rotational atherec-
tomy, and conventional balloon angioplasty. The 786 pts received adjunctive pharmaco-
therapy consisting of the anti-platelet drugs aspirin, clopidogrel (at least 300 mg net dose
prior to PCI), and eptifibatide (double bolus at time of PCI), and a reduced final dose of
the anti-thrombin drug enoxaparin (administered prior to PCI, as part of routine care for
initially presenting problem). Pts received no other scheduled, specific anti-thrombin ther-
apy. Results. Pts received as their final enoxaparin dose, on average, 0.51 mg/kg subcu-
taneously, 7.8 hours prior to PCI. The technical success rate for PCI was 99.6%. During
the first 24 hours following PCI, there was one major adverse event (0.1%). The inci-
dence of non-Q wave myocardial infarction was 1.8%. The incidences of major and minor
bleeding complications were 0.2% and 1.8%, respectively, and the incidence of thromb-
ocytopenia was 1.4%. During the subsequent 30 days following PCI, there were four
major adverse clinical events (0.5%). Conclusions. For higher risk PCI, eptifibatide-based
anti-platelet therapy accompanied by only limited, specific anti-thrombin therapy appears
efficacious and safe.
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Background: Current recommendations for PCI in subcutaneous enoxaparin (SQE)
treated acute coronary syndrome (ACS) pts are based on studies in which pts received
SQE for >2 days and a steady state may have been reached. Data on adequacy of anti-
coagulation for PCI in SQE treated pts presenting for early cardiac catheterization (cath)
are limited. Methods: We prospectively studied 77 ACS pts treated with SQE (1mg/kg
bid) who presented for cath <12 hrs from the last SQ dose. Pts were divided into two
groups based on number of doses of SQE received prior to cath, <2 doses (n=42) or >2
doses (n=35). Anti-Xa levels and ENOX clotting time (a novel point of care test for enox-
aparin) were measured in all pts during cath. An anti-Xa level of >0.8 IU/ml was consid-
ered as therapeutic anticoagulation for PCI. Additional IV enoxaparin during PCI was
given at the discretion of the physician. ENOX clotting time was correlated with anti-Xa
levels. Results: Baseline characteristics and medications were similar between the 2
groups. The median (IQ range) number of doses of SQE prior to cath in the <2 and > 2
doses group were 2.0 (1.0, 2.0) and 4.0 (3.0, 6.0) respectively. The median elapsed time
between last SQE and cath was 4.5 (3.0, 6.0) hrs in <2 doses group and 4.0 (2.0, 5.0) hrs
in >2 doses group (p=0.1). IV GP 2b/3a inhibitors use (45% vs. 43%, p=0.8) and PCI
rates (41% vs. 51%, p=0.3) were not different. Median anti-Xa level was 0.8 (0.6, 1.1) IU/
ml in <2 doses group and 1.0 (0.8, 1.3) IU/ml in > 2 doses group (p=0.05). The % of pts
with anti-Xa <0.8 IU/ml was 43% in <2 doses group compared with 20% in >2 doses
group (p=0.033). Overall 29% of pts in both groups received additional anticoagulation in
the cath lab. In-hospital death (2.4 vs. 0%), MI (4.8 vs. 2.9%), urgent TVR (2.4% vs. 0%),
and major bleeding (2.4 vs. 2.9%) were not significantly different between the groups.
The overall correlation between ENOX clotting time and anti-Xa levels was modest
(r=0.5, p<0.001). However, 85% of pts with ENOX clotting time >250s had anti-Xa levels
>0.8 IU/ml. Conclusions: ACS pts on SQE presenting early for cath have lower median
anti-Xa levels and frequently have anti-Xa levels <0.8 IU/ml. Most pts with ENOX clotting
time of >250s at cath have anti-Xa levels >0.8 IU/ml.
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Genesis Medical Center, Davenport, IA
Background: Guidelines for the management of peripheral vascular disease (PVD) rec-
ommend surgical revascularization for superficial femoral artery (SFA) chronic total
occlusions (CTO) >5cm (TASC Type D lesions)[1]. We report our experience on the tech-
nical feasibility and impact on quality of life using standard stenting techniques to treat
“surgical disease” of the lower extremities.
Methods: We reviewed our database for patients that underwent percutaneous revascu-
larization for SFA CTO. Traditional primary stenting techniques were employed utilizing
the self-expanding, nitinol SMART® stent (Cordis, Miami, FL). The Walking Impairment
Questionnaire[2] (WIQ range: 0 to 14,080) was used to assess quality of life pre and post
procedure. Ankle-brachial index (ABI) was obtained pre and post procedure.
Results: 44 patients (51 legs) underwent attempted percutaneous revascularization for
SFA CTO TASC Type D lesions at Genesis Medical Center, Davenport, IA, USA between
August 2000 and July 2003. Successful revasc 90.2%, Ave CTO length (cm) 15.5 + 9.9,
Ave stent length (cm) 23.2 + 12.2, Min stent diam (mm) 7.0 + 0.6, Min artery diam (mm)
5.9 + 0.6, Stents deployed 2.7 + 1.7; Pre-WIQ 722 + 1503, Post-WIQ 8421 + 5741
(p<0.0005), Median delta-WIQ 7405 (95% CI: 6555 to 9245); Pre-ABI 0.61 + 0.18, Post-
ABI 0.91 + 0.19 (p<0.0005) , Median delta-ABI 0.27 (95% CI: 0.21 to 0.33); Median fol-
low-up (days) 374 + 321; Repeat revasc: PTA 13.7%, surgery 3.9%, Amputation 2.0%;
Death (at follow up) 6.8%
Conclusions: Traditional “surgical disease” can be treated with a high degree of success
by standard angioplasty and nitinol stenting techniques. Patients have a significant
improvement in their quality of life, and objective improvement on serial non-invasive test-
ing. Repeat revascularization rates are reasonably low, and parallel historical surgical
data. A minimally invasive percutaneous approach should become the initial preferred
method of revascularization for lower extremity PVD regardless of the TASC lesion type.
[1] TransAtlantic Inter-Society Consensus Statement. J of Vasc Surg (suppl). Jan
2000;31(1):S1-S296.
[2] Circulation. 1995;92:614-21.
